Evidence map›Paper›PMID 35729639›Full record

ArticleJournal of translational medicine2022

Comprehensive analysis of microglia gene and subpathway signatures for glioma prognosis and drug screening: linking microglia to glioma.

Chunlong Zhang, Jiaxin Zhao, Wanqi Mi, Yuxi Zhang, Xiaoling Zhong, Guiyuan Tan, Feng Li, Xia Li, Yanjun Xu, Yunpeng Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chunlong Zhang *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Jiaxin Zhao *Center of Cerebrovascular Disease, Zhuhai People's Hospital, Zhuhai Hospital Affiliated With Jinan University, Zhuhai, 519000, China.
Wanqi Mi *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yuxi ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xiaoling ZhongCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Guiyuan TanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Feng LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. lixia@hrbmu.edu.cn.
Yanjun XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. xuyanjun@hrbmu.edu.cn.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. zhangyp@hrbmu.edu.cn.
Harbin Medical University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most common malignant tumors in the brain. Previous studies have revealed that, as the innate immune cells in nervous system, microglia cells were involved in glioma pathology. And, the resident microglia displayed its specific biological roles which distinguished with peripheral macrophages. In this study, an integrated analysis was performed based on public resource database to explore specific biological of microglia within glioma. Through comprehensive analysis, the biological characterization underlying two conditions, glioma microglia compared to glioma macrophage (MicT/MacT) as well as glioma microglia compared to normal microglia (MicT/MicN), were revealed. Notably, nine core MicT/MicN genes displayed closely associations with glioma recurrence and prognosis, such as P2RY2, which was analyzed in more than 2800 glioma samples from 25 studies. Furthermore, we applied a random walk based strategy to identify microglia specific subpathways and developed SubP28 signature for glioma prognostic analysis. Multiple validation data sets confirmed the predictive performance of SubP28 and involvement in molecular subtypes. The associations between SuP28 score and microglia M1/M2 polarization were also explored for both GBM and LGG types. Finally, a comprehensive drug-subpathway network was established for screening candidate medicable molecules (drugs) and identifying therapeutic subpathway targets. In conclusions, the comprehensive analysis of microglia related gene and functional signatures in glioma pathobiologic events by large-scale data sets displayed a framework to dissect inner connection between microglia and glioma, and identify robust signature for glioma clinical implications.

Indexed as

Brain NeoplasmsGliomaDrug Evaluation, PreclinicalHumansMacrophagesMicrogliaPrognosisReceptors, Purinergic P2Y2P2RY2 protein, humanReceptors, Purinergic P2Y2BiomarkerBrain diseaseMicrogliancRNARegulatory network

Identifiers

PMID35729639
PMCPMC9210642
OpenAlexW4283220813

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.